Résumé
Le rôle des récepteurs NMDA au sein des circuits excitateurs centraux en fait une cible privilégiée de la recherche orientée vers des thérapeutiques neuromodulatrices. La douleur appartient aux domaines d'application pour ce type de nouvelles approches médicamenteuses. Malgré la méconnaissance précise de son site d'action, le dextromethorphan, réputé en tant qu'antitussif, est un vieux compagnon de l'arsenal thérapeutique du praticien. Des expériences récentes ont révélé les propriétés neuromodulatrices intéressantes du dextromethorphan et de son métabolite principal dans des modèles expérimentaux de douleur chez l'animal. Dans des conditions expérimentales chez l'homme, la molécule mère semble prédominer dans la prévention de l'hyperalgésie centrale.
Summary
The role of NMDA receptors in the central excitatory pathways makes them a privileged research object towards neuromodulatory therapeutics. Pain belongs to the fields of application for this type of new drug therapies. Although its mechanism of action is still relatively misunderstood, dextromethorphan, a reknowned cough medicine, is an old companion to the physician's therapeutic arsenal. Recent experiences point to its fascinating neuromodulatory properties, as well as those of its main metabolite, in animal experimental models of pain. Experimental conditions in man point to the predominance of the main molecule in the prevention of central hyperalgesia.
This is a preview of subscription content, log in via an institution to check access.
Bibliographie
Barnard E.A.: Ionotropic glutamate receptors: new types and new concepts.TiPS 18, 141–148, 1997.
Britton P., Lu M.X.C., Laskosky M.S. andTortella F.C.: Dextromethorphan protects againts cerebral injury following transient, but not permanent, focal ischemia in rats.Life Sci. 60, 1729–1740, 1997.
Capon D.A., Bochner F., Kerry N., Mikus G., Danz C. andSomogyi A.A.: The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans.Clin. Pharmacol. Ther. 60, 295–307, 1996.
Chaplan S.R., Malmberg A.B. andYaksh T.L.: Efficacy of spinal NMDA receptor antagonism in formalin hyperalgesia and nerve injury evoked allodynia in the rat.J. Pharmacol. Exp. Ther. 280, 829–838, 1997.
Danysz W., Zajaczkowksi W. andParsons C.G.: Modulation of learning processes by ionotropic glutamate receptor ligands.Behavioural Pharmacology 6, 455–474, 1995.
Dayer P., Leemann T. andStriberni R.: Dextromethorphan O-demethylation in liver microsomes as a prototype reaction to monitor cytochrome P-450 db1 activity.Clin. Pharmacol. Ther. 45, 34–40, 1989.
Dickenson A.H.: Neurophysiology of opioid poorly responsive pain.Cancer Surv. 21, 5–16, 1994.
Dingledine R., McBrain C.J. andMcNamara J.O.: Excitatory amino acid receptors in epilepsy.TiPS 11, 334–338, 1990.
Doble A.: Excitatory amino acid receptors and neurodegenration.Thérapie 50, 319–337, 1995.
Kondo Oestreicher M., Desmeules J., Piguet V., Allaz A.F. etDayer P.: Influences génétiques et environnementales sur la neuromodulation et l'effet antinociceptif du dextromethorphan.Schweiz. Med. Wochenschr. 128, 212–215, 1998.
Kornhuber J. undWeller M.: Neue therapeutische Möglichkeiten mit niederaffinen NMDA-Rezeptorantagonisten.Nervenarzt 67, 77–82, 1996.
Langer S.Z.: 25 years since the discovery of presynaptic receptors: present knowledge and future perspectives.TiPS 18, 95–99, 1997.
Louvel E., Hugon J. andDoble A.: Therapeutic advances in amyotrophic lateral sclerosis.TiPS 18, 196–203, 1997.
McQuay H.J., Carrol D., Jadad A.R., Glynn C.J., Jack T., Moore R.A. andWiffen P.J.: Dextromethorphan for the treatment of neuropathic pain: a double-blind, randomised controlled corossover trial with integral n-of-1 design.Pain 59, 127–133, 1994.
Meldrum B. andGarthwaite J.: Excitatory amino acid neurotoxicity and neurodegenerative disease.TiPS 11, 3793–87, 1990.
Müller W.E., Mutschler E. andRiederer P.: Noncompetitive NMDA receptor antagonists with fast open-channel bocking kinetics and strong voltage-dependency as potential therapeutic agents for Alzheimer's dementia.Pharmacopsychiat. 28, 113–124, 1995.
Nelson K.A., Park K.M., Robinovitz E., Tsigos C. andMax M.B.: High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia.Neurology 48, 1212–1218, 1997.
Portenoy R.K.: Adjuvant analgesic agents. In Pain and palliative care,Hematol. Oncol. Clin. North Am. 10, 103–119, 1996.
Price D.D., Mao J., Frenk H. andMayer D.J.: The N-methyl-D-aspartate receptor antagonist dextromethorphan selectively reduces temporal summation of second pain in man.Pain 59, 165–174, 1994.
Schmider J., Greenblatt D.J., Fogelman S.M., Von Moltke L.L., andShader R.I.: Metabolism of dextromethorphanin vitro: involvement of cytochromes P450 2D6 and 3A3/4, with a possible role of 2E1.Biopharm. Drug Disp. 18, 227–240, 1997.
Solberg Y. andBelkin M.: The role of excitotoxicity in organophosphorous nerve agents central poisoning.TiPS 18, 183–185, 1997.
Thatte U. andDahanukar S.: Apoptosis, clinical relevance and pharmacological manipulation.Drugs 54, 511–532, 1997.
Tortella F.C., Pellicano M. andBowery N.G.: Dextromethorphan and neuromodulation: old drug coughs up new activities.TiPS 10, 501–507, 1989.
Wachtel H. andTurski L.: Glutamate: a new target in schizophrenia?TiPS 11, 219–220, 1990.
Wong B.Y., Coulter D.A., Choi D.W. andPrince D.A.: Dextrorphan and dextromethorphan, common antitussives, are antiepileptic and antagonize N-methyl-D-aspartate in brain slices.Neurosci. Lett. 85, 261–266, 1988.
Zivin J.A.: Neuroprotective therapies in stroke.Drugs 54 Suppl. 3, 83–89, 1997.
Author information
Authors and Affiliations
About this article
Cite this article
Oestreicher, M.K., Desmeules, J.A., Piguet, V. et al. Renouveau pour un vieux compagnon: l'exemple du dextromethorphan. Doul. et Analg. 11, 83–86 (1998). https://doi.org/10.1007/BF03013288
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF03013288